Y Intercept Hong Kong Ltd Cuts Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Y Intercept Hong Kong Ltd lessened its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 96.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,185 shares of the life sciences company's stock after selling 76,094 shares during the quarter. Y Intercept Hong Kong Ltd's holdings in Illumina were worth $415,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Industrial Alliance Investment Management Inc. bought a new position in shares of Illumina in the second quarter worth approximately $34,000. Massmutual Trust Co. FSB ADV lifted its stake in shares of Illumina by 65.1% in the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after buying an additional 168 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in Illumina during the second quarter valued at approximately $61,000. Private Trust Co. NA lifted its position in Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company's stock valued at $62,000 after purchasing an additional 212 shares during the period. Finally, Mizuho Securities Co. Ltd. bought a new position in Illumina during the second quarter valued at approximately $63,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ILMN. Stephens increased their price objective on shares of Illumina from $170.00 to $184.00 and gave the company an "overweight" rating in a research report on Tuesday, November 12th. Argus upgraded shares of Illumina from a "hold" rating to a "buy" rating and set a $150.00 price objective on the stock in a research report on Wednesday, August 28th. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Hsbc Global Res upgraded shares of Illumina from a "hold" rating to a "strong-buy" rating and set a $180.00 price objective on the stock in a research report on Thursday, October 17th. Finally, Barclays increased their price objective on shares of Illumina from $135.00 to $145.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. Eight investment analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $165.95.

Illumina Price Performance

ILMN stock traded down $1.28 during trading on Tuesday, hitting $143.12. 1,771,055 shares of the company's stock traded hands, compared to its average volume of 2,008,106. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43. The business has a fifty day simple moving average of $144.42 and a 200 day simple moving average of $129.20. The stock has a market capitalization of $22.70 billion, a price-to-earnings ratio of -14.37 and a beta of 1.11.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business's revenue was down 3.5% on a year-over-year basis. During the same quarter last year, the business earned $0.33 EPS. As a group, research analysts expect that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.